Abstract:One receptor, DDR2, both promotes the differentiation of bone-depositing cells and prevents the differentiation of bone-resorbing cells. Reorganizing receptor complexes to rebuild bone The skeleton undergoes continuous turnover mediated by osteoblasts and osteoclasts, which respectively deposit and resorb bone. When this turnover is dysregulated, skeletal diseases such as osteoporosis—a disease characterized by bone loss—can occur. The receptor tyrosine kinase DDR2 (discoidin domain receptor 2) tilts the balance in favor of bone formation. Zhang et al. determined that, in addition to promoting osteoblast differentiation, DDR2 inhibited osteoclast differentiation and bone matrix resorption in culture. In a mouse model of osteoporosis, viral-mediated delivery of DDR2 increased bone density. By forming a complex with the receptors Neuropilin-1 and PlexinA1, DDR2 blocked PlexinA1-mediated stimulation of osteoclastogenesis. Thus, increasing the abundance of DDR2 in both types of bone precursor cells may be therapeutically beneficial for osteoporosis patients. Osteoporosis is a disease characterized by abnormal skeletal fragility due to an imbalance in bone homeostasis. Finding therapeutic targets that promote bone formation is valuable for treating osteoporosis. Discoidin domain receptor 2 (DDR2) is a receptor tyrosine kinase that promotes the differentiation of bone-depositing cells, osteoblasts, and bone formation. We investigated the role of DDR2 in osteoclastogenesis, the formation of cells responsible for bone resorption. We found that, although differentiated osteoclasts had catalytically active DDR2, its abundance was decreased. Overexpression of DDR2 inhibited the expression of osteoclastic markers, osteoclast maturation, and osteoclast-mediated bone resorption in a culture model of bone matrix. Conversely, knocking down Ddr2 through RNA interference accelerated osteoclast differentiation and bone resorption in mice. Further, we identified the co-receptor Neuropilin-1 (Nrp1) as a DDR2-interacting protein. DDR2 facilitated the binding of Nrp1 and the co-receptor PlexinA1 by forming a DDR2-Nrp1-PlexinA1 complex, which blocked PlexinA1-mediated stimulation of osteoclastogenesis. DDR2 prevented PlexinA1 from interacting with the receptor TREM2 and the adaptor DAP12. Moreover, knocking down Nrp1 rescued the expression of osteoclastic markers observed in DDR2-overexpressing cells, whereas ectopic expression of Nrp1 in DDR2-silenced cells inhibited the induction of osteoclastogenesis. Nrp1 enhanced the function of DDR2 in promoting osteoblast differentiation and bone formation in mice. In an ovariectomized mouse model of osteoporosis, adenovirus-mediated delivery of DDR2 to the femur bone alleviated osteopenic phenotypes. Our results revealed that DDR2 functions as an inhibitor of osteoclastogenesis, as well as a promoter of osteoblastogenesis, suggesting that enhancing DDR2 may be therapeutic for patients with osteoporosis.

Targeting adipocytic discoidin domain receptor 2 impedes fat gain while increasing bone mass

DDR2 (discoidin domain receptor 2) suppresses osteoclastogenesis and is a potential therapeutic target in osteoporosis

FATP2 Regulates Osteoclastogenesis by Increasing Lipid Metabolism and ROS Production.

Ablation of Discoidin Domain Receptor 1 Provokes an Osteopenic Phenotype by Regulating Osteoblast/Osteocyte Autophagy and Apoptosis

Discoidin domain receptor 1-deletion ameliorates fibrosis and promotes adipose tissue beiging, brown fat activity, and increased metabolic rate in a mouse model of cardiometabolic disease

Ablation of Fat Cells in Adult Mice Induces Massive Bone Gain

Discoidin Receptor 2 Controls Bone Formation and Marrow Adipogenesis

Ablation of myeloid discoidin domain receptor 2 exacerbates arthritis and high fat diet induced inflammation

NDR2 is Critical for the Osteoclastogenesis by Regulating ULK1-mediated Mitophagy.

DEPTOR exacerbates bone–fat imbalance in osteoporosis by transcriptionally modulating BMSC differentiation

12-Deoxyphorbol 13-Acetate Inhibits RANKL-induced Osteoclastogenesis Via the Attenuation of MAPK Signaling and NFATc1 Activation

Exploring the Cellular and Molecular Mechanism of Discoidin Domain Receptors (DDR1 and DDR2) in Bone Formation, Regeneration, and Its Associated Disease Conditions

Discoidin Domain Receptor 2 Facilitates Prostate Cancer Bone Metastasis Via Regulating Parathyroid Hormone-Related Protein.

Targeting Kindlin-2 in adipocytes increases bone mass through inhibiting FAS/PPAR γ/FABP4 signaling in mice

Low-density lipoprotein receptor deficiency reduced bone mass in mice via the c-fos/NFATc1 pathway

Adipocyte-specific deletion of Dbc1 does not recapitulate healthy obesity phenotype but suggests regulation of inflammation signaling

Impdh2 deficiency suppresses osteoclastogenesis through mitochondrial oxidative phosphorylation and alleviates ovariectomy-induced osteoporosis

Dlk2 Interacts with Syap1 to Activate Akt Signaling Pathway During Osteoclast Formation

Doubly truncated FosB isoform (Delta2DeltaFosB) induces osteosclerosis in transgenic mice and modulates expression and phosphorylation of Smads in osteoblasts independent of intrinsic AP-1 activity

Dexamethasone shifts bone marrow stromal cells from osteoblasts to adipocytes by C/EBPalpha promoter methylation

Exercise Promotes Bone Marrow Microenvironment by Inhibiting Adipsin in Diet-Induced Male Obese Mice